 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Preoperative chemotherapy combined with immunotherapy is safe and feasible for patients with resectable NSCLC

Front Oncol: Preoperative chemotherapy combined with immunotherapy is safe and feasible for patients with resectable NSCLC

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

cell culture media

non intent bpa

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Removable non-small cell lung cancer ( NSCLC ) neoadjuvant chemotherapy + immunotherapy is an important research topic
.

Despite the potential benefits of this approach, adverse events related to neoadjuvant chemotherapy + immunotherapy may affect surgery

Removable non-small cell lung cancer ( NSCLC ) neoadjuvant chemotherapy + immunotherapy is an important research topic

The study was conducted from May 2019 to March 2021
.

Patients who were 18 years of age or older, diagnosed with stage Ib-IIIb NSCLC and received neoadjuvant chemotherapy + immunotherapy and then undergoing surgery

The study was conducted from May 2019 to March 2021

From May 2019 to March 2021, 20 patients received neoadjuvant chemotherapy combined with immunotherapy

The chemotherapy regimen included 2 cases of carboplatin combined with pemetrexed, 10 cases of carboplatin combined with paclitaxel, 3 cases of cisplatin combined with gemcitabine, 2 cases of cisplatin combined with pemetrexed, and 3 cases of cisplatin combined with paclitaxel

Treatment methods and efficacy

CT evaluation after neoadjuvant therapy showed that 15 patients (75%) had partial remission, and 5 patients (25%) had stable disease
.

The final pathological examination showed that 8 patients had major pathological remission (MPR), of which 5 cases (25%) were pathological complete remission (pCR)

CT evaluation after neoadjuvant therapy showed that 15 patients (75%) had partial remission, and 5 patients (25%) had stable disease

Twelve patients (60%) underwent thoracotomy; 8 patients (40%) underwent minimally invasive surgery, of which 4 received robotic thoracoscopic surgery (RATS) and 4 received video-assisted thoracoscopic surgery (VATS)

Surgery related information

During neoadjuvant therapy, 13 of 20 patients (65%) experienced grade 1 treatment-related adverse reactions, and 1 of 20 patients (10%) experienced grade 2 adverse reactions
.

No adverse reactions of grade 3 or more occurred

During neoadjuvant therapy, 13 of 20 patients (65%) experienced grade 1 treatment-related adverse reactions, and 1 of 20 patients (10%) experienced grade 2 adverse reactions

Adverse events

In summary, studies have shown that preoperative chemotherapy combined with immunotherapy in patients with resectable NSCLC is safe and feasible
.

Studies have shown that preoperative chemotherapy combined with immunotherapy in patients with resectable NSCLC is safe and feasible
.
Studies have shown that preoperative chemotherapy combined with immunotherapy in patients with resectable NSCLC is safe and feasible
.

Original source:

Hu Y, Ren SY, Wang RY, Zeng C, Li JN, Xiao P, Wu F, Yu FL and Liu WL (2021) Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer.
Front.
Oncol.
11:684070 .
doi: 10.
3389/fonc.
2021.
684070

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.